CLINICAL TRIALS PROFILE FOR ESREBOXETINE
✉ Email this page to a colleague
Clinical Trials for Esreboxetine
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00752505 ↗ | A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia. | Completed | Pfizer | Phase 2 | The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make decisions or problem solve. The study is also designed to assess if there is a difference in cognitive function between fibromyalgia patients and matched control subjects. |
| NCT00796601 ↗ | Maintenance of Efficacy. | Withdrawn | Pfizer | Phase 3 | The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo. |
| NCT00800956 ↗ | Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine | Completed | Pfizer | Phase 1 | The purpose of the study is to learn more about how esreboxetine is handled by the body i.e. the absorption, metabolism and excretion of esreboxetine. |
| NCT00809289 ↗ | Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers | Completed | Pfizer | Phase 1 | This Phase 1 study will assess the effects of esreboxetine on the heart. In particular the effects on a specific electrocardiogram (ECG) measurement called QTc will be measured. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Esreboxetine
Condition Name
Clinical Trial Locations for Esreboxetine
Trials by Country
Clinical Trial Progress for Esreboxetine
Clinical Trial Phase
Clinical Trial Sponsors for Esreboxetine
Sponsor Name
